Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259050 · ClinicalTrials.gov registry record · Phase 1
Safety Study of High Doses of Zinc in ALS Patients
A Phase 1 study, sponsored by Phoenix Neurological Associates.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01259050 is a Phase 1 study that has completed, run by Phoenix Neurological Associates. The registered enrollment target is 10 participants.
The verdict
NCT01259050, a Phase 1 study, has completed, sponsored by Phoenix Neurological Associates.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.
Interventions
- DRUG Zinc and Copper
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01259050
The ClinicalTrials.gov registry entry for NCT01259050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phoenix Neurological Associates, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zinc and Copper is the first listed.
NCT01259050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01259050 about?
NCT01259050 is a clinical study titled "Safety Study of High Doses of Zinc in ALS Patients". The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.
What is the current status of trial NCT01259050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01259050?
The interventions under investigation include: Zinc and Copper (DRUG).
Who is sponsoring clinical trial NCT01259050?
This trial is sponsored by Phoenix Neurological Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.